We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: CAR-T
MedXY News
EnglishTag

CAR-T

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis
Clinical UpdatesCAR-Tfludarabine

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

By MedXY|Jun 9, 2026

A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing b

EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Hematology-Oncology
CAR-T
cellular therapy

EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy

By MedXY|May 30, 2026

The 2024 EBMT activity report marks a major cellular therapy milestone, showing record allogeneic HCT, continued CAR-T expansion, and persistent disparities in donor use, pediatric activity, and country-level access.

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data
Hematology-OncologyBCMACAR-T

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

By MedXY|Dec 9, 2025

Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and sho

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity
Hematology-OncologyB-ALLCAR-T

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

By MedXY|Nov 24, 2025

A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activ

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Hematology-OncologyCAR-TGPRC5D

Fully Human anti-GPRC5D CAR T (RD118) Produces High-Rate, Durable Remissions in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

By MedXY|Nov 17, 2025

In a phase 1 study of 18 heavily pretreated patients, the fully human VHH-based anti-GPRC5D CAR T-cell therapy RD118 achieved a 94.4% overall response rate, 72.2% CR/sCR, median PFS 18.2 months, and an acceptable safety profile with predomi

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients
Clinical UpdatesCAR-TCAR-T Therapy

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY|Sep 30, 2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities